Novo Nordisk A/S
This is how exposed European Big Pharma is to the U.S.
Novo Nordisk CEO Maziar Mike Doustdar shakes hands with U.S. President Donald Trump during an event to announce a deal with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White House in Washington, D.C., U.S., November 6, 2025. Jonathan Ernst | […]
Read More
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial. The company also said it has filed for Food and Drug Administration approval of the daily […]
Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever. 2026 is likely the year that two new oral weight loss […]
Read More
High-end Swiss chocolatier Läderach rules out U.S. production despite tariff shock
Key Points CEO Johannes Läderach categorically stated “never” when asked if his company ever considered opening a production site in the U.S. to circumvent export duties. The Swiss chocolatier faced a shock over the summer as U.S. tariffs on Swiss imports jumped to 39%, though they have since settled at 15%. The levies came on […]
Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]
Read More
Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday said its next-generation obesity drug delivered strong weight loss and reduced knee arthritis pain in a late-stage study, clearing the first of several upcoming trials on the weekly injection. The […]
Read More
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company’s pill
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Reuters Pfizer on Tuesday said it has struck an […]
Read More
Unilever spinoff Magnum Ice Cream debuts on Amsterdam stock market
Packets of Walls Cornetto, Magnum and Ben & Jerry’s ice cream are displayed on March 20, 2024. John Keeble | Getty Images News | Getty Images Magnum Ice Cream Company, now the world’s largest standalone ice cream business, debuted on the Amsterdam stock exchange on Monday. The stock opened at 12.20 euros, slightly below its […]
Read More
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the […]
Read More
Eli Lilly’s price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk
Sopa Images | Lightrocket | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. No-tech November Last week’s recovery rally allowed the Dow Jones Industrial Average and S&P 500 to both finish their seventh […]
Read More